This segment focuses on the research, development, and clinical trials of vaccines for various infectious diseases. Zhifei Biological Products invests heavily in R&D, utilizing advanced technologies such as conjugate vaccine technology and recombinant protein technology. The company's pipeline includes vaccines for meningococcal disease, pneumococcal disease, and other infectious diseases. This segment aims to improve public health by preventing infectious diseases and reducing their impact on patient populations. Market positioning is strong in China, with a growing global footprint through partnerships and collaborations. Future opportunities include expanding the vaccine portfolio and entering new markets. Regulatory aspects involve rigorous clinical trials and adherence to national and international standards. Partnerships with global pharmaceutical companies like GSK are key to market expansion and technology transfer.

This segment encompasses the sales, marketing, and distribution of Zhifei's vaccine products. It involves building and maintaining a strong sales force, establishing distribution networks, and ensuring the efficient delivery of vaccines to healthcare providers and disease control institutions. The company focuses on building strong relationships with key opinion leaders and healthcare professionals to promote its products. This segment's impact is directly related to the accessibility of vaccines, contributing to improved public health outcomes. Market positioning is dependent on effective sales and marketing strategies, as well as strong relationships with government agencies and healthcare providers. Future opportunities include expanding the sales team, entering new markets, and leveraging digital marketing channels. Regulatory aspects involve compliance with advertising and promotion regulations. Partnerships with distributors and healthcare organizations are crucial for market penetration and product reach.